An observational study in Alagille Syndrome, sponsored by Ipsen. Recruiting at 10 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Ipsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alagille Syndrome with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Alagille Syndrome · United States.
Among the 17 studies in Alagille Syndrome with a site in United States, this one is the only one that started in 2025, is one of 9 observational ones, and was the 16th registered.
31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.
Browse Alagille Syndrome studies →5 of the 17 studies in Alagille Syndrome with a site in United States are open now. Recruiting first, the newest first:
Digestive Care, Inc. · Sites in United States
Ages 7–50
Mirum Pharmaceuticals, Inc. · Sites in United States
Sanford Health · Sites in United States
Stanford University · Sites in United States
Ages up to 17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 30 is below the median of 120 across 15 observational studies indexed under Alagille Syndrome.
Median enrollment 37 across the 7 interventional studies, 70 across the 9 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 17 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 291 studies on the registry; 19 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 6 studies filed under Alagille Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Alagille Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05035030Phase 3Albireo, an Ipsen CompanyLong-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | 2027-02-15 |
| NCT07335523Digestive Care, Inc.Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alagille Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.
Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.
The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Patients diagnosed with ALGS who start treatment with odevixibat (Bylvay) will be enrolled into the registry. Patients who started odevixibat treatment before the implementation of the registry study may also be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percentage of participants with Alagille syndrome (ALGS) who are treated with odevixibat and undergo biliary diversion surgery or liver transplantation.
Time frame: From first dose to end of study (approximately 5 years data collection)
Surgical biliary diversion-free survival
Defined as time from the start of odevixibat treatment to the first occurrence of surgical biliary diversion or death.
Time frame: From first dose to end of study (approximately 5 years data collection)
Liver transplant-free survival
Defined as time from the start of odevixibat treatment to the first occurrence of liver transplant or death.
Time frame: From first dose to end of study (approximately 5 years data collection)
Overall survival
Defined as time from the start of odevixibat treatment to death.
Time frame: From first dose to end of study (approximately 5 years data collection)
Change from Baseline in Weight
This endpoint will measure the change in participants' weight from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations.
Time frame: From first dose to end of study (approximately 5 years data collection)
Change from Baseline in Height
This endpoint will measure the change in participants' height from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations.
Time frame: From first dose to end of study (approximately 5 years data collection)
Percentage of participants with Adverse Events (AEs) associated with fat-soluble vitamin (FSV) deficiencies and their possible sequelae.
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
Percentage of participants with suspected hepatotoxic Adverse events (AEs) requiring interruption of odevixibat
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From signing of the ICF to 180 days after the last dose intake of odevixibat
Percentage of participants with bleeding AEs
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From signing of the ICF to 180 days after the last dose intake of odevixibat
Percentage of participants with AEs
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From signing of the ICF to 180 days after the last dose intake of odevixibat
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2030, 67 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.